These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37330416)

  • 41. Advances in covalent kinase inhibitors.
    Abdeldayem A; Raouf YS; Constantinescu SN; Moriggl R; Gunning PT
    Chem Soc Rev; 2020 May; 49(9):2617-2687. PubMed ID: 32227030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity
    Saramago LC; Santana MV; Gomes BF; Dantas RF; Senger MR; Oliveira Borges PH; Ferreira VNDS; Dos Santos Rosa A; Tucci AR; Dias Miranda M; Lukacik P; Strain-Damerell C; Owen CD; Walsh MA; Ferreira SB; Silva-Junior FP
    J Chem Inf Model; 2023 May; 63(9):2866-2880. PubMed ID: 37058135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.
    Aljoundi A; Bjij I; El Rashedy A; Soliman MES
    Protein J; 2020 Apr; 39(2):97-105. PubMed ID: 32072438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.
    Wang L; Yu Z; Wang S; Guo Z; Sun Q; Lai L
    Eur J Med Chem; 2022 Dec; 244():114803. PubMed ID: 36209629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
    Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
    J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL
    Stille JK; Tjutrins J; Wang G; Venegas FA; Hennecker C; Rueda AM; Sharon I; Blaine N; Miron CE; Pinus S; Labarre A; Plescia J; Burai Patrascu M; Zhang X; Wahba AS; Vlaho D; Huot MJ; Schmeing TM; Mittermaier AK; Moitessier N
    Eur J Med Chem; 2022 Feb; 229():114046. PubMed ID: 34995923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
    Yang Y; Shu YZ; Humphreys WG
    Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Theory and applications of covalent docking in drug discovery: merits and pitfalls.
    Kumalo HM; Bhakat S; Soliman ME
    Molecules; 2015 Jan; 20(2):1984-2000. PubMed ID: 25633330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
    Tan H; Hu Y; Jadhav P; Tan B; Wang J
    J Med Chem; 2022 Jun; 65(11):7561-7580. PubMed ID: 35620927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distinguishing the optimal binding mechanism through reversible and irreversible inhibition analysis of HSP72 protein in cancer therapy.
    Aljoundi A; El Rashedy A; Soliman MES
    Comput Biol Med; 2021 May; 132():104301. PubMed ID: 33751994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics.
    Yu HS; Gao C; Lupyan D; Wu Y; Kimura T; Wu C; Jacobson L; Harder E; Abel R; Wang L
    J Chem Inf Model; 2019 Sep; 59(9):3955-3967. PubMed ID: 31425654
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
    Sivakumar D; Stein M
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Merging the Versatile Functionalities of Boronic Acid with Peptides.
    Tan Y; Wu J; Song L; Zhang M; Hipolito CJ; Wu C; Wang S; Zhang Y; Yin Y
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.
    Banerjee S
    Biophys Chem; 2021 Feb; 269():106510. PubMed ID: 33285430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the I7L Protease: A Rational Design for Anti-Monkeypox Drugs?
    Dodaro A; Pavan M; Moro S
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
    Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33503819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection.
    Ge R; Shen Z; Yin J; Chen W; Zhang Q; An Y; Tang D; Satz AL; Su W; Kuai L
    SLAS Discov; 2022 Mar; 27(2):79-85. PubMed ID: 35063690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
    Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
    J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer.
    Zhang B; Zhu C; Chan ASC; Lu G
    Eur J Med Chem; 2023 Aug; 256():115457. PubMed ID: 37207533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.